Alzheimer’s disease affects roughly 32 million people worldwide, and that number is expected to climb to 152 million by 2050. Despite decades of research and billions in pharmaceutical investment, there is still no cure. The medications that exist today manage symptoms, and mostly in the early stages. They do not stop the disease from progressing.
That gap has pushed researchers toward less conventional directions, and one of the more compelling threads right now involves a drug that has been used in psychiatry for 75 years. Lithium, long established as a treatment for bipolar disorder, is now being studied as a potential tool for slowing Alzheimer’s progression, specifically at much lower doses than psychiatric treatment typically requires.
Why lithium is getting a second look
The case for lithium in Alzheimer’s research is not new, but it is gaining momentum. Over the past two and a half decades, studies have accumulated evidence that lithium carries neurotrophic and neuroprotective properties, meaning it may support the survival and health of brain cells under stress.
A study published in JAMA Psychiatry, led by Dr. Husseini K. Manji, a prominent researcher in the field, makes the argument directly. Existing Alzheimer’s therapies tend to focus on single targets, most commonly amyloid plaques. Alzheimer’s, however, is not a single-pathway disease. It involves mitochondrial decay, oxidative stress, and multiple cellular vulnerabilities that a one-target approach consistently fails to address.
Low-dose lithium, according to Manji and his team, may be capable of working across several of those pathways simultaneously.
How lithium works in the brain
At low doses, lithium appears to function as a kind of master regulator for the brain’s cellular defense system. It promotes the production of brain-derived neurotrophic factor, a protein that supports the growth and maintenance of neurons. It also blocks harmful enzymes associated with neurodegeneration and improves how brain cells produce and use energy.
The result, researchers suggest, is that vulnerable brain cells in an Alzheimer’s environment may have a better chance of surviving and maintaining function longer.
The dosing question has historically been a sticking point. Standard lithium doses used in bipolar treatment can be difficult for older adults to tolerate, with concerns centered on kidney and thyroid function. But the emerging research focuses specifically on lower doses, where the neuroprotective effects appear to remain present while the side effect profile becomes significantly more manageable.
What experts are saying about lithium
Dr. Laura Nisenbaum, executive director of drug development at the Alzheimer’s Drug Discovery Foundation, has responded to the research with measured enthusiasm. She pointed to lithium’s multi-target profile as a meaningful advantage given how complex the disease actually is.
Dr. Dung Trinh, an internist and chief medical officer of the Healthy Brain Clinic, brought a more cautious perspective. He acknowledged the findings as promising but stressed that rigorous clinical trials are still needed to confirm both safety and effectiveness. He also raised concerns about patients attempting to self-medicate, given lithium’s potential for interactions with other drugs.
That caution is not a dismissal. It reflects where the science currently sits. Promising is not the same as proven, and the path from compelling research to clinical standard is rarely short.
What comes next for lithium research
The immediate priority is well-structured clinical trials in patients with early-stage Alzheimer’s or mild cognitive impairment. Researchers will be tracking cognitive outcomes, neurodegeneration biomarkers, and quality of life over time.
If those trials bear out what the existing research suggests, low-dose lithium could represent something rare in Alzheimer’s care: an affordable, accessible option with a mechanism broad enough to address more than one dimension of the disease at once. That is not a small thing in a field that has spent decades chasing single-target solutions with limited results.
